Introduction
Heterosexual transmission accounted for the majority of an estimated 5.4 million new infections in 1999, approximately 2.3 million of which were in women [1] . There is a broad consensus that female-controlled, over-the-counter methods to prevent HIV infection offer an opportunity to impact on the epidemic. At present, the range of products available is limited to the female condom, as the preliminary results from the COL-1492 Study assessing the ef®cacy of nonoxynol-9, a licensed spermicide, indicated that the risk of HIV infection was higher in women exposed to nonoxynol-9 compared with a lubricant control [2] . Since these results were presented at the World AIDS Conference held in Durban in July 2000, nonoxynol-9 studies have been suspended, attention has turned away from surfactant compounds, and there has been a critical appraisal of the pre-clinical and clinical methods to assess candidate microbicides.
A number of novel products are at an advanced stage of development, and several research groups are preparing for phase III ef®cacy trials. Early safety trials have been completed and a preliminary exploration of the acceptability pro®le of products conducted, some of these in target populations for phase III. Important parallel studies include investigation of the distribution and retention of gel in the vagina using magnetic resonance imaging. At the same time in-vitro experiments continue to identify new agents with activity against HIV, which are not toxic to epithelial cells. This review will attempt to illustrate the process of evaluation for candidate microbicides, which justi®es proceeding to early clinical assessment (phase I trials), and the evidence required to support large-scale ef®cacy trials (phase III).
Why microbicides?
Although consistent condom use offers effective protection against the acquisition of HIV, studies with longer follow-up suggest that there are dif®culties in sustaining use in the absence of ongoing support [3 . ]. Male condoms are widely available and affordable to populations at risk, but women have to negotiate their use, and sex inequalities, cultural norms and the fear of violence are obstacles to this. Offering a choice of barrier products appears to increase the proportion of sexual acts that are protected compared with offering a single product [4] . For women in whom childbearing is a priority, the addition of products that permit conception, while offering protection against sexually transmitted infections (STIs) and HIV, is likely to facilitate this further.
An assessment of the potential market undertaken in 11 countries involving consumer research in women aged 16±45 years, and interviews with healthcare professionals and other experts, found a high level of interest driven by personal concern among all income groups [5 . ]. In only three of these 11 countries were condoms used by the majority of women interviewed.
What is required to proceed to large-scale clinical trials?
To justify further investigation there must be preclinical evidence of activity against HIV and ideally other STIs, as well as a satisfactory safety pro®le when human epithelial cells are exposed to the candidate agent. Greenhead et al. [6
. . ] described an in-vitro explant model of cervical tissue obtained from hysterectomy specimens and maintained in culture medium, in which candidates can be assessed for toxicity and the ability to inhibit HIV infection. Further evidence to support ef®cacy can be provided by challenge experiments, and nonoxynol-9 has consistently provided protection against intravaginal challenge in the primate model, although not at 100%. Weber et al. [7 . ] reported that three out of four exposed to nonoxynol-9, four out of eight exposed to PRO2000/5 (Interneuron Pharmaceuticals Inc, Lexington, Massachusetts, USA) and two out of four exposed to dextrin sulphate were protected from intravaginal challenge with the chimaeric simian immunode®ciency virus/HIV SHIV 89.6PD in the rhesus macaque model. However, one out of four control animals was not infected, and for this reason, together with a lack of validation of the animal model, the results must be interpreted with caution. The prevention of HIV infection could also be achieved through an indirect mechanism by protection against other STIs [8] . The herpes simplex virus type 2 mouse system therefore offers a second animal model in which compounds can be evaluated, and Maguire et al. [9 . ] compared eight candidates including BufferGel (ReProtect LLC, Baltimore, Maryland, USA), nonoxynol-9 and Carraguard (PC-503; Clean Chemical Sweden AB, Borlange, Sweden), which afforded 65, 90 and 100% protection, respectively, when compared with controls all of which became infected.
Before a product can enter clinical trial a pre-clinical pro®le of the pharmacokinetics, systemic absorption and toxicity must be built using established methodology recommended by the regulatory authorities. These experiments are usually conducted in small animals, and although there is no ideal model in which to explore local toxicity, most is known about the rabbit vagina. ]. Epithelial disruptions must be perceived as clinically important in terms of an increased risk of HIV acquisition, as it is recognized that ulcerative STIs are associated with higher rates of HIV infection. However, the relationship may not be direct. Research by Stafford et al. [13] suggested that the cellular in®ltrate associated with an in¯ammatory response after exposure to nonoxynol-9 may be a key factor, as they found an increase in number of target cells for HIV infection in the genital epithelium. This response can only be assessed by histology, a more invasive procedure, and one which most research groups have stopped conducting after standardization of the colposcopic assessment. The current guidelines advise that the simpli®ed colposcopic assessment be continued in phase I to collect further data to inform future revisions of the recommendations. An interesting contribution to the evidence comes from Van de Wijgert et al. [14 . ], who reported the results of colposcopic examinations in Zimbabwean women who were users or non-users of intravaginal cleaning agents or traditional substances. Of those classi®ed as`non-users', 91% ®nger-cleansed the vagina with plain water. Of 430 examinations performed on 162 women, 698 lesions were identi®ed: 11% of these could not be accounted for by the presence of a pathogen, referred to as signal lesions. Abrasions accounted for 5% of the signal lesions. There was no association between these lesions and intravaginal practices.
As nonoxynol-9 is a licensed spermicide in use for many years in many countries, there were suf®cient human data to support safety prior to the COL-1492 phase III clinical trial of a low dose (52.5 mg). However, concerns were raised that nonoxynol-9-induced epithelial disruption may facilitate HIV infection, and so the safety pro®le was formally investigated in phase I trials [12 . ] and in a sub-study of 320 women participating in COL-1492 who had had at least one colposcopic examination [15 . ]. The incidence of colposcopic lesions was low, with no difference between the active and placebo groups, and the investigators concluded that multiple daily use was non-toxic. Forbes and Heise [16] offered three explanations for the increased incidence of HIV infection in the nonoxynol-9 group: that nonoxynol-9 increased the risk of HIV infection through an irritant effect; that Replens (Unipath, Bedford, UK) (the lubricant control) reduced transmission; or that both effects were exerted. Further evidence of the toxicity of nonoxynol-9 was provided by Phillips et al. [17 . ], who investigated the effects on rectal epithelium, and found sheets of epithelial cells in the lavage specimens collected 15 min after the application of two different formulations of nonoxynol-9. The full results of COL-1492 are awaited, and WHO are coordinating the publication of recommendations on the future use of nonoxynol-9 products after a consultative meeting to review the safety of nonoxynol-9 as a contraceptive and an anti-HIV compound.
Meanwhile attention has turned away from surfactants to products with a different, non-cytotoxic, mechanism of action. ]. The designs of the trials vary slightly, but epithelial disruption remains a primary toxicity end-point in all the studies, usually assessed colposcopically using standardized methods referred to above. Other information that is speci®cally collected includes genital symptoms, such as irritation and discharge. The data from these safety trials are suf®ciently encouraging for research groups to continue to prepare for phase III ef®cacy trials.
Critical parallel studies
There are two areas of research activity that provide particularly important information to investigators preparing for large scale clinical trials. These are discussed below.
Distribution and retention of product
These characteristics are likely to be key to the success of candidate agents, but without proof of ef®cacy there are no data to inform the required distribution and contact time for gel to be effective. Although the site of HIV transmission has not been de®nitively elucidated, it is logical to assume that cervical coverage will be important, if not essential [24 . ]. Barnhart et al. [25 . ] used magnetic resonance imaging to visualize the vaginal distribution of nonoxynol-9 gel in one subject, 10 min after self-administration of 5 ml gel with à standard' applicator. The majority of material was in the vaginal canal, but some had spread into the endocervix and some had been leaked from the introitus. This ®rst case report requires validation in larger numbers and at other centres, but could prove to be an important addition to the assessment of candidate agents.
Applicators and delivery systems
The paper by Barnhardt et al. [25 . ] referred to à standard' clinical applicator, but there are many licensed devices. The most common in the USA and UK for repeated use is the plastic Ortho applicator (Janssen± Cilag Ltd, High Wycombe, Buckinghamshire, UK), which is approximately 11 cm long and has a screw thread inside to attach to a tube. Gel is squeezed out to ®ll the applicator, which is then inserted into the vagina as far as possible while the woman is in the supine position, and is applied by holding the barrel ®rmly and depressing the plunger. The principal alternative design is the single-use pre-®lled applicator, which has the advantage of guaranteeing sterility. Coetzee et al. [26 . ] explored the acceptability of single-use Micralax applicators (Norden Pac International AB, Kalmar, Sweden) in 28 HIV-negative female volunteers recruited from family planning and general health clinics in two centres in South Africa (Cape Town and Pretoria). Participants were asked to return used applicators for weighing in order to work out the average volume of gel dispensed. The applicators were pre-®lled with 7 ml and delivered a mean volume of 4.7 ml (range 2.1±7.5 ml). Although only 22 participants completed the study, the majority found the applicator easy to use, and liked the study product (gel and applicator). This study underlines the value of early assessment in order to optimize the use of product and delivery system in phase III.
Long-acting sustained release of spermicide', which is inserted as a pessary, and becomes a bioadhesive ®lm remaining in place for at least 12 h, offers the possibility of an extended duration of action by the slow release of active ingredients [27 . ,28 . ]. To date this has only been explored with nonoxynol-9, but the technology could be suitable for use with other small molecules.
Acceptability
Understanding why and how women use vaginal products is critical to the effective planning and interpretation of phase III trials. It is plausible that agents will prevent HIV infection in some cultural settings and not in others, and validation of tools to assess the social and behavioural factors that determine use is just as important as standardizing the clinical examination. Much can be learnt from the experience with contraceptive products and barrier methods, and Elias and Coggins [3 . ] have published a comprehensive review of work in these ®elds. It is likely that formulation will have an impact on acceptability [29 . ]. All the products poised to enter phase III trials are gels, and most research groups are exploring pre-®lled, singleuse applicators. The literature to support these choices is not vast, and few studies have been conducted in target populations for phase III. There are practical dif®culties in implementing these studies in a timely manner because safety data are usually insuf®cient at the point when information is required to assist manufacturing decisions.
Acceptability among men should not be forgotten, and withdrawal from microbicide studies has already been attributed to the negative views of male partners [26 . ]. A widely held view that women would welcome`stealth' products that they could use without their partner's knowledge was not substantiated in a US telephone survey in women [30] .
What is happening earlier in the pipeline?
The products and their respective stage of development are listed in the Alliance database [31
. . ], which includes products with anti-HIV activity as well as delivery systems. Many of these have not yet reached the literature, but the article attempts to highlight references that demonstrate the range of evaluations contributing to the evidence that justi®es clinical development.
Preliminary in-vitro assessments explore anti-HIV activity through a range of pH and in the presence of sperm, as well as toxicity to human epithelial cells. Spermicidal activity is of interest as it is likely that the use of microbicide will be optimized by offering women a choice of products with and without contraceptive properties. Pokeweed antiviral protein, a 29 000 M r protein that can be puri®ed in large amounts from the leaves of Phytolacca americana, has antiviral activity attributed to the inhibition of protein synthesis, without being toxic to human sperm or epithelial cells, as detailed in the experiments conducted by D'Cruz and Uckun [32 . ].
WHI-07 is a derivative of zidovudine, with potent anti-HIV activity in vitro and a favourable toxicity pro®le in cell cultures and in vivo in mice and the rabbit vaginal model. A 13-week intravaginal exposure experiment has been undertaken in mice [33 . ], and quantitative analysis suggests that neither WHI-07 nor its metabolites can be absorbed through the vaginal epithelium. There was no systemic toxicity or loss of subsequent fertility.
In order to optimize candidate agents, and in particular to identify suitable combinations, it is necessary to understand the molecular mechanisms underlying activity. Mori and Boyd [34] evaluated the effects of cyanovirin-N, a recombinant protein based on an extract from the cyanobacterium Nostoc ellipsosporum, on the binding of soluble gp120 to cell-associated CD4. They demonstrated that it is the type of CD4 cell (soluble or membrane associated) that determines in-vitro activity rather than the type of gp120 (soluble or virionassociated). Further work is needed to resolve the molecular explanation for these differences.
Cellulose acetate phthalate is a compound that has been used for many years in coating enteric tablets, and therefore has an established safety record. It has in-vitro activity against a wide range of STIs including HIV [35] , and activity against herpes simplex virus type 2 in the mouse model [36] , reviewed by Neurath [37] . Manson et al. [38 . ] conducted an experiment in 16 macaques exposed to two different formulations (six per group), before vaginal challenge with SIV, and found some evidence of protection, although not all control animals were infected by a single inoculation of virus. This further emphasizes the dif®culty in interpreting the animal models, when the vaginal route does not always result in infection, and the numbers per group are small.
Conclusion
This has been a signi®cant year for microbicides, starting with the preliminary report of COL14-92. Although the results were disappointing, they have not impeded scienti®c activity or donor interest, lessons have been learnt [39 . ], and at least four programmes of research are preparing to enter phase III with novel, non-surfactant, products [40 . ]. All of these are in the public sector, but this year has seen a clear demonstration of international demand for such products and the implied potential for pro®t [5 . ,30] . Public demand will be determined by effectiveness, and it is likely that the major pharmaceutical companies will wait for a demonstration of this before committing substantial resources. It is clear that the initiative currently lies within the public sector, and this offers a unique opportunity to guarantee affordability and delivery of product to those who need it. . 12 Coggins C, Elias C. Safety of three formulations of nonoxynol-9 containing vaginal spermicides. N-9 Formulation Preferences Study Group Committee. Int J Gynaecol Obstet 2000; 68:267±268. The safety report on women who participated in the nonoxynol-9 formulation study using film (70 mg), pessary (suppository, 150 mg) and gel (200 mg) each for 4 weeks, concluding that the products were well accepted and tolerated. 
